BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Market Cap | 21.581 Billion | Shares Outstanding | 184.03 Million | Avg 30-day Volume | 1.642 Million |
P/E Ratio | 187.4947 | Dividend Yield | 0.0 | EPS | 4.33 |
Price to Revenue | 7.834 | Debt to Equity | 0.243 | EBITDA | 218.821 Million |
Price to Book Value | 3.4438 | Operating Margin | 5.386699999999999 | Enterprise Value | 15.197 Billion |
Current Ratio | 5.149 | EPS Growth | 1.15 | Quick Ratio | 3.25 |
1 Yr BETA | 0.742 | 52-week High/Low | 117.77 / 70.73 | Profit Margin | 4.1782 |
Operating Cash Flow Growth | -35.6021 | Altman Z-Score | 6.1816 | Free Cash Flow to Firm | -96.173 Million |
Earnings Report | 2023-02-22 |
Please sign in first
none
83.5 Thousand total shares from 15 transactions
79.9 Thousand total shares from 7 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
AJER JEFFREY ROBERT EVP, CHIEF COMMERCIAL OFFICER |
|
41,088 | 2023-01-25 | 10 |
BIENAIME JEAN JACQUES CHIEF EXECUTIVE OFFICER |
|
1,284,641 | 2023-01-13 | 13 |
MUELLER BRIAN EVP, CHIEF FINANCIAL OFFICER |
|
32,746 | 2023-01-13 | 10 |
|
10,905 | 2022-10-31 | 2 | |
DAVIS GEORGE ERIC EVP, CHIEF LEGAL OFFICER |
|
55,251 | 2022-08-09 | 7 |
GUYER CHARLES GREG EVP, CHIEF TECHNICAL OFFICER |
|
42,168 | 2022-08-08 | 3 |
|
40,840 | 2022-05-24 | 1 | |
|
108,994 | 2022-05-24 | 2 | |
|
85,568 | 2022-05-24 | 2 | |
|
28,950 | 2022-05-24 | 2 | |
|
23,390 | 2022-05-24 | 1 | |
|
26,310 | 2022-05-24 | 1 | |
|
26,619 | 2022-05-24 | 2 | |
|
12,450 | 2022-05-24 | 1 | |
|
18,890 | 2022-05-24 | 1 | |
BURKHART ERIN GVP, CHIEF ACCOUNTING OFFICER |
|
28,620 | 2022-05-16 | 2 |
FUCHS HENRY J PRESIDENT, WORLDWIDE R&D |
|
325,595 | 2022-03-15 | 2 |
ACOSTA ANDREA GVP, CHIEF ACCOUNTING OFFICER |
|
18,122 | 2021-04-30 | 0 |
|
42,840 | 2021-03-05 | 0 | |
BAFFI ROBERT PRESIDENT, GLOBAL MFG/TECH OPS |
|
189,020 | 2020-03-20 | 0 |
|
25,590 | 2019-06-04 | 0 | |
SPIEGELMAN DANIEL K EVP, CHIEF FINANCIAL OFFICER |
|
47,686 | 2019-04-30 | 0 |
|
3,300 | 2016-07-15 | 0 | |
|
32,750 | 2015-06-10 | 0 | |
|
11,875 | 2015-06-10 | 0 | |
|
11,875 | 2015-06-10 | 0 | |
WOOD MARK VP, HUMAN RESOURCES |
|
57,603 | 2013-05-22 | 0 |
ASELAGE STEVE EVP, CHIEF BUSINESS OFFICER |
|
378,405 | 2012-07-02 | 0 |
COOPER JEFFREY H SVP, CHIEF FINANCIAL OFFICER |
|
194,881 | 2012-04-30 | 0 |
|
35,000 | 2010-03-08 | 0 | |
KAKKIS EMIL D CHIEF MEDICAL OFFICER |
|
580,378 | 2009-03-02 | 0 |
SWIEDLER STUART J SVP, CLINICAL AFFAIRS |
|
No longer subject to file | 2008-07-07 | 0 |
|
135,000 | 2006-06-14 | 0 | |
|
197,444 | 2006-02-24 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-27 21:35:00 -0500 | 2023-01-25 | M | 46,800 | d | 0 | direct | yes | |||||||||
2023-01-27 21:35:00 -0500 | 2023-01-25 | M | 2,200 | d | 0 | direct | yes | |||||||||
2023-01-27 21:35:00 -0500 | 2023-01-25 | S | 4,175 | $116.15 | d | 41,088 | direct | yes | ||||||||
2023-01-27 21:35:00 -0500 | 2023-01-25 | S | 44,825 | $115.65 | d | 45,263 | direct | yes | ||||||||
2023-01-27 21:35:00 -0500 | 2023-01-25 | M | 49,000 | $67.81 | a | 90,088 | direct | yes | ||||||||
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-18 21:41:30 -0500 | 2023-01-17 | M | 10,000 | d | 193,130 | direct | yes | ||||||||
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-18 21:41:30 -0500 | 2023-01-17 | S | 10,000 | $111.55 | d | 320,424 | direct | yes | 1.4194 | 7.1245 | 7.1245 | 6 | 0.0 | 1 | |
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-18 21:41:30 -0500 | 2023-01-17 | M | 10,000 | $67.81 | a | 330,424 | direct | yes | 1.4194 | 7.1245 | 7.1245 | 6 | 0.0 | 1 | |
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-18 21:41:30 -0500 | 2023-01-13 | M | 10,000 | d | 203,130 | direct | yes | ||||||||
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-18 21:41:30 -0500 | 2023-01-13 | S | 10,000 | $112.25 | d | 320,424 | direct | yes | 1.4194 | 7.1245 | 7.1245 | 6 | 0.0 | 1 | |
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-01-18 21:41:30 -0500 | 2023-01-13 | M | 10,000 | $67.81 | a | 330,424 | direct | yes | 1.4194 | 7.1245 | 7.1245 | 6 | 0.0 | 1 | |
2023-01-17 21:57:08 -0500 | 2023-01-13 | M | 2,500 | d | 5,000 | direct | yes | |||||||||
2023-01-17 21:57:08 -0500 | 2023-01-13 | S | 2,500 | $114.50 | d | 27,746 | direct | yes | -1.3461 | 4.8243 | 4.8243 | 6 | -1.3461 | 2 | ||
2023-01-17 21:57:08 -0500 | 2023-01-13 | M | 2,500 | $63.10 | a | 30,246 | direct | yes | -1.3461 | 4.8243 | 4.8243 | 6 | -1.3461 | 2 | ||
2022-12-15 18:22:45 -0500 | 2022-12-13 | M | 2,500 | d | 7,500 | direct | yes | |||||||||
2022-12-15 18:22:45 -0500 | 2022-12-13 | S | 2,500 | $107.50 | d | 27,746 | direct | yes | -1.8595 | -3.9492 | 0.0 | 1 | -3.9492 | 6 | ||
2022-12-15 18:22:45 -0500 | 2022-12-13 | M | 2,500 | $63.10 | a | 30,246 | direct | yes | -1.8595 | -3.9492 | 0.0 | 1 | -3.9492 | 6 | ||
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-12-15 16:43:26 -0500 | 2022-12-13 | S | 1,000 | $106.89 | d | 320,424 | direct | -1.8595 | -3.9492 | 0.0 | 1 | -3.9492 | 6 | ||
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-12-06 21:09:42 -0500 | 2022-12-02 | S | 471 | $103.97 | d | 322,453 | direct | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
2022-12-06 21:29:18 -0500 | 2022-12-02 | M | 3,761 | d | 0 | direct | ||||||||||
2022-12-06 21:29:18 -0500 | 2022-12-02 | M | 2,139 | d | 0 | direct | ||||||||||
2022-12-06 21:29:18 -0500 | 2022-12-02 | S | 3,761 | $104.50 | d | 27,746 | direct | yes | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
2022-12-06 21:29:18 -0500 | 2022-12-02 | M | 3,761 | $67.81 | a | 31,507 | direct | yes | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
2022-12-06 21:29:18 -0500 | 2022-12-02 | S | 2,139 | $104.50 | d | 27,746 | direct | yes | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
2022-12-06 21:29:18 -0500 | 2022-12-02 | M | 2,139 | $67.81 | a | 29,885 | direct | yes | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
2022-12-06 21:29:18 -0500 | 2022-12-02 | S | 1,101 | $104.50 | d | 27,746 | direct | yes | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-12-06 21:09:42 -0500 | 2022-12-02 | S | 69 | $104.06 | d | 321,424 | direct | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-12-06 21:09:42 -0500 | 2022-12-02 | S | 100 | $104.00 | d | 321,493 | direct | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-12-06 21:09:42 -0500 | 2022-12-02 | S | 260 | $103.98 | d | 321,593 | direct | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 | |
BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-12-06 21:09:42 -0500 | 2022-12-02 | S | 600 | $103.97 | d | 321,853 | direct | 0.6751 | 4.5231 | 7.4838 | 9.5284 | 25 | -2.9704 | 18 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 22:15:03 UTC | 4.0691 | 0.2509 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 21:45:04 UTC | 4.0691 | 0.2509 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 21:15:04 UTC | 4.0691 | 0.2509 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 20:45:03 UTC | 4.0691 | 0.2509 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 20:15:04 UTC | 4.0691 | 0.2509 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 19:45:03 UTC | 4.0691 | 0.2509 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 19:15:03 UTC | 4.0691 | 0.2509 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 18:45:04 UTC | 4.0697 | 0.2503 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 18:15:03 UTC | 4.0697 | 0.2503 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 17:45:03 UTC | 4.0697 | 0.2503 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 17:15:04 UTC | 4.0697 | 0.2503 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 16:45:03 UTC | 4.0688 | 0.2512 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 16:15:03 UTC | 4.0688 | 0.2512 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 15:45:03 UTC | 4.0688 | 0.2512 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 15:15:04 UTC | 4.0688 | 0.2512 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 14:45:04 UTC | 4.0688 | 0.2512 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 14:15:03 UTC | 4.0688 | 0.2512 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 13:45:03 UTC | 4.07 | 0.25 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 13:15:03 UTC | 4.07 | 0.25 | 4300000 |
BIOMARIN PHARMACEUTICAL INC BMRN | 2023-01-27 12:45:03 UTC | 4.07 | 0.25 | 4300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AGF Investments Trust- AGFIQ U.S. Market Neutral Momentum Fund | BMRN | -304.0 shares, $-26657.76 | 2020-12-31 | N-PORT |
FundVantage Trust- Gotham Master Neutral Fund | BMRN | -16.0 shares, $-1217.28 | 2020-09-30 | N-PORT |
Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund | BMRN | -900.0 shares, $-75096.0 | 2021-06-30 | N-PORT |
Guidestone Funds- Strategic Alternatives Fund | BMRN | -1041.0 shares, $-88245.57 | 2022-09-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | BMRN | -1608.0 shares, $-136310.16 | 2022-09-30 | N-PORT |
AQR Funds- AQR Alternative Risk Premia Fund | BMRN | -653.0 shares, $-55354.81 | 2022-09-30 | N-PORT |
GMO TRUST- GMO Alternative Allocation Fund | BMRN | -1200.0 shares, $-121176.0 | 2022-11-30 | N-PORT |
GMO TRUST- GMO Strategic Opportunities Allocation Fund | BMRN | -1000.0 shares, $-100980.0 | 2022-11-30 | N-PORT |
GMO TRUST- GMO Implementation Fund | BMRN | -24100.0 shares, $-2433618.0 | 2022-11-30 | N-PORT |
GMO TRUST- GMO Benchmark-Free Fund | BMRN | -8300.0 shares, $-838134.0 | 2022-11-30 | N-PORT |